Additionally, the role of splenectomy in TTP treatment has gained attention, with some literature suggesting its potential benefit by reducing antibody production against ADAMTS13. It is essential to maintain a high level of clinical suspicion for TMA, as this can lead to the early initiation of treatment, including empirical therapy, which may improve patient prognosis. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.